Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia


Disclosures: S.F.C. has consulted for Imago Biosciences. M.B.G has received honorarium from Dava Oncology. A.D.V. received travel support from Mission Bio and is on the Editorial Advisory Board of Hematology News. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis. He receives research support from and consulted for Celgene and Roche, research support from Prelude Therapeutics, and has consulted for Novartis and Gilead. He has received honoraria from Lilly and Amgen for invited lectures. MST receives research support from Arog, Cellerant, ADC therapeutics, Orsenix and Biosight. He is on the following advisory boards: Daiichi-Sankyo, Roche, Abbvie. M.R. has consulted for Agios, BD Biosciences and Celgene, and has received contract research funding from Agios, Bayer, BMS and Roche.